Mosaic trisomy 16 ascertained through amniocentesis: evaluation of 11 new cases.
Trisomy 16, once thought to result uniformly in early pregnancy loss, has been detected in chorionic villus samples (CVS) from on-going pregnancies and was initially ascribed to a second, nonviable pregnancy. Prenatally detected trisomy 16 in CVS and its resolution to disomy has led to the reexamination of the viability of trisomy 16. This study evaluates 11 cases of mosaic trisomy 16 detected through second trimester amniocentesis. In 9 of the 11 cases, amniocenteses were performed in women under the age of 35 because of abnormal levels of maternal serum alpha-fetoprotein (MSAFP) or maternal serum human chorionic gonadotropin (MShCG). The other two amniocenteses were performed for advanced maternal age. Five of the 11 pregnancies resulted in liveborn infants, and six pregnancies were electively terminated. The liveborn infants all had some combination of intrauterine growth retardation (IUGR), congenital heart defects (CHD), or minor anomalies. Two of them died neonatally because of complications of severe congenital heart defects. The three surviving children have variable growth retardation, developmental delay, congenital anomalies, and/or minor anomalies. In the terminated pregnancies, the four fetuses evaluated by ultrasound or autopsy demonstrated various congenital anomalies and/or IUGR. Cytogenetic and fluorescent in situ hybridization studies identified true mosaicism in 5 of 10 cases examined, although the abnormal cell line was never seen in more than 1% of cultured lymphocytes. Placental mosaicism was seen in all placentas examined and was associated with IUGR in four of seven cases. Maternal uniparental disomy was identified in three cases. Mosaic trisomy 16 detected through amniocentesis is not a benign finding but associated with a high risk of abnormal outcome, most commonly IUGR, CHD, developmental delay, and minor anomalies. The various outcomes may reflect the diversity of mechanisms involved in the resolution of this abnormality. As 80% of these patients were ascertained because of the presence of abnormal levels of MSAFP or MShCG, the increased use of maternal serum screening should bring more such cases to clinical attention.
Hsu
W T
WT
Department of Pediatrics, Rush Medical College, Chicago, Illinois, USA. whsu@rush.edu
Shchepin
D A
DA
Mao
R
R
Berry-Kravis
E
E
Garber
A P
AP
Fischel-Ghodsian
N
N
Falk
R E
RE
Carlson
D E
DE
Roeder
E R
ER
Leeth
E A
EA
Hajianpour
M J
MJ
Wang
J C
JC
Rosenblum-Vos
L S
LS
Bhatt
S D
SD
Karson
E M
EM
Hux
C H
CH
Trunca
C
C
Bialer
M G
MG
Linn
S K
SK
Schreck
R R
RR
D000649:Amniocentesis; D002885:Chromosomes, Human, Pair 16 / Q000235:genetics*; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D018895:Microsatellite Repeats; D009030:Mosaicism / Q000235:genetics*; D011247:Pregnancy; D011256:Pregnancy Outcome / Q000235:genetics; D014314:Trisomy / Q000235:genetics*; D000509:alpha-Fetoproteins
D000509:alpha-Fetoproteins